Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its holdings in shares of Baxter International Inc (NYSE:BAX) by 1.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 78,082 shares of the medical instruments supplier’s stock after purchasing an additional 1,163 shares during the quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd.’s holdings in Baxter International were worth $5,329,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of BAX. Cypress Capital Group purchased a new stake in Baxter International in the second quarter valued at approximately $211,000. Sterling Capital Management LLC purchased a new stake in Baxter International in the second quarter valued at approximately $278,000. Piedmont Investment Advisors LLC lifted its stake in Baxter International by 22.5% in the second quarter. Piedmont Investment Advisors LLC now owns 184,491 shares of the medical instruments supplier’s stock valued at $11,169,000 after buying an additional 33,886 shares during the last quarter. Gofen & Glossberg LLC IL lifted its stake in Baxter International by 1.3% in the second quarter. Gofen & Glossberg LLC IL now owns 15,354 shares of the medical instruments supplier’s stock valued at $930,000 after buying an additional 203 shares during the last quarter. Finally, Beaton Management Co. Inc. purchased a new stake in Baxter International in the second quarter valued at approximately $412,000. Hedge funds and other institutional investors own 83.54% of the company’s stock.

In related news, SVP Giuseppe Accogli sold 28,641 shares of the company’s stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $67.00, for a total transaction of $1,918,947.00. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, SVP Jeanne K. Mason sold 33,350 shares of the company’s stock in a transaction on Monday, December 4th. The stock was sold at an average price of $65.25, for a total value of $2,176,087.50. Following the transaction, the senior vice president now directly owns 124,609 shares in the company, valued at approximately $8,130,737.25. The disclosure for this sale can be found here. 0.05% of the stock is owned by corporate insiders.

A number of equities research analysts have weighed in on BAX shares. Zacks Investment Research upgraded Baxter International from a “hold” rating to a “buy” rating and set a $72.00 price objective for the company in a research note on Tuesday, October 24th. Royal Bank of Canada reiterated a “hold” rating and issued a $66.00 price objective on shares of Baxter International in a research note on Wednesday, November 22nd. Raymond James Financial upgraded Baxter International from a “market perform” rating to an “outperform” rating and set a $73.00 price objective for the company in a research note on Wednesday, January 3rd. JPMorgan Chase & Co. upgraded Baxter International from a “neutral” rating to an “overweight” rating in a research note on Tuesday, January 2nd. Finally, Bank of America reiterated a “hold” rating on shares of Baxter International in a research note on Wednesday, November 22nd. Seven investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company. Baxter International currently has a consensus rating of “Buy” and a consensus price target of $70.36.

Shares of Baxter International Inc (BAX) opened at $62.56 on Friday. Baxter International Inc has a 52 week low of $48.40 and a 52 week high of $72.58. The company has a current ratio of 2.80, a quick ratio of 2.22 and a debt-to-equity ratio of 0.37. The company has a market capitalization of $35,713.73, a P/E ratio of 26.33, a PEG ratio of 1.86 and a beta of 0.78.

Baxter International (NYSE:BAX) last released its quarterly earnings results on Thursday, February 1st. The medical instruments supplier reported $0.64 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.59 by $0.05. Baxter International had a return on equity of 15.12% and a net margin of 6.79%. The business had revenue of $2.77 billion during the quarter, compared to analysts’ expectations of $2.77 billion. During the same quarter in the prior year, the business earned $0.57 earnings per share. The company’s quarterly revenue was up 4.9% compared to the same quarter last year. research analysts forecast that Baxter International Inc will post 2.78 EPS for the current fiscal year.

WARNING: “Baxter International Inc (BAX) Position Raised by Mitsubishi UFJ Kokusai Asset Management Co. Ltd.” was first reported by Watch List News and is the property of of Watch List News. If you are accessing this piece on another site, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The original version of this piece can be read at https://www.watchlistnews.com/baxter-international-inc-bax-position-raised-by-mitsubishi-ufj-kokusai-asset-management-co-ltd/1855354.html.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.

Want to see what other hedge funds are holding BAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Baxter International Inc (NYSE:BAX).

Institutional Ownership by Quarter for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.